Aaron Ondrey - 08 Sep 2023 Form 4 Insider Report for Mirati Therapeutics, Inc.

Role
Interim CFO
Signature
/s/ John Moriarty, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
08 Sep 2023
Net transactions value
+$299,972
Form type
4
Filing time
12 Sep 2023, 17:30:32 UTC
Next filing
03 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRTX Common Stock Award $299,972 +8,412 +60% $35.66 22,440 08 Sep 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This represents a Performance Share Unit Award and shares shall vest in full on the earlier of (i) 90 days following commencement of employment of a permanent CFO, (ii) involuntary termination of employment (not for Cause).